# US 2019/0243945 A1 · Leveraging Genomic, Phenotypic and Pharmacological Data to Cure Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0243945 A1
- Document ID: US20190243945A1
- Status: Published application
- Kind: A1
- Application number: 15/954,575
- Filed: 2018-04-16
- Published: 2019-08-08
- Earliest claimed: 2018-02-02
- Inventors: Richard Postrel
- Web page: https://patentgrep.com/patent/US20190243945A1

## CPC

- G16C 20/40: Searching chemical structures or physicochemical data
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- C40B 30/00: Methods of screening libraries
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G06F 16/2455: Query execution
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 40/20: Supervised data analysis
- G16C 20/50: Molecular design, e.g. of drugs
- G16C 20/70: Machine learning, data mining or chemometrics
- G16C 20/90: Programming languages; Computing architectures; Database systems; Data warehousing
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 70/40: relating to drugs, e.g. their side effects or intended usage
- A61K 31/52: Purines, e.g. adenine
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention provides a process and method for repurposing existing compounds by leveraging genomic, phenotypic and pharmacological data to cure disease. Applying advanced mathematical analytics using massively interconnected computing capabilities to identify target rich sets of existing compounds available for animal testing at the earliest stage in the process collapses cycle time of development, dramatically reducing costs. Target rich sets obtained through this invention produce compounds or compositions which each have a demonstrated ability to modulate disease or an associated phenotypic expression. By rendering the mechanism of action irrelevant, this invention collapses the time and cost to discovery of an efficacious drug from decades to days and from $Billions to $Millions.

## Claims

### Claim 1

A method of identifying a compound that modulates at least one of a group of diseases, said method comprising:
a. selecting a symptom or disease;
b. feeding said symptom or disease into a search field of a structured database;
c. querying said at least one structured database for content of one or a plurality of records referencing said first symptom;
d. selecting at least one record referencing said first symptom;
e. correlating said first symptom with at least one recorded feature of said at least one record;
f. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
g. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
h. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom; and:
i. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in g and remaining after h;
j. determining effect of said one or more compounds and/or compositions;
k. selecting one or more compounds and/or compositions determined to have desired effect; and
l. identifying at least one of one or more compounds and/or compositions selected in l as said new pharmaceutical composition; or:
j. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in h;
k. optionally noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
l. selecting at least a second compound or composition, said at least one second compound or composition selected to contribute modulation of an activity selected from the group consisting of: countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, O2 consumption and interferon production;
m. confirming desired activity of said at least one second compound or composition; and
n. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

### Claim 2

A method for identifying a new pharmaceutical composition for treating a disease, said method comprising:
a. selecting a first symptom of a first disease;
b. providing an identification of said first disease;
c. accessing at least one structured database;
d. querying said at least one structured database for content of one or a plurality of records referencing said first symptom;
e. selecting at least one record referencing said first symptom;
f. correlating said first symptom with at least one recorded feature of said at least one record;
g. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
h. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
i. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom; and:
j. delivering to a physical, chemical and/or bio model at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in h and remaining after i;
k. determining effect of said one or more compounds and/or compositions;
l. selecting one or more compounds and/or compositions determined to have desired effect; and
m. identifying at least one of one or more compounds and/or compositions selected in l as said new pharmaceutical composition; or:
j. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in i;
k. optionally noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
l. selecting at least a second compound or composition, said at least one second compound or composition selected to contribute modulation of an activity selected from the group consisting of: a compound countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, O2 consumption and interferon production;
m. confirming desired activity of said at least one second compound or composition; and
n. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

### Claim 3 (depends on 1)

The method of claim 1 further comprising:
m or o. delivering said new pharmaceutical composition to at least one individual.

### Claim 4 (depends on 2)

The method of claim 2 further comprising:
n or o. delivering said new pharmaceutical composition to at least one individual.

### Claim 5 (depends on 3)

The method of claim 3 wherein said delivering comprises providing an individual with a substance selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray.

### Claim 6 (depends on 4)

The method of claim 4 wherein said delivering comprises providing an individual with a substance selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray.

### Claim 7

A method for producing a new pharmaceutical composition, said method comprising:
a. selecting a first symptom of a first disease;
b. providing an identification of said first disease;
c. accessing at least one structured database;
d. querying said at least one structured database for content of one or a plurality of records selected from the group consisting of: record(s) referencing said first symptom and record(s) referencing said first disease;
e. selecting at least one first record obtained from d;
f. selecting at least one chemical compound relating to said at least one first record;
g. querying at least one structured database for content of one or a plurality of records referencing said at least one chemical compound to obtain a listing comprising diseases and symptoms relating to said compound;
h. querying at least one structured database with results of said listing obtained from the query in g to obtain a compilation of compounds associated with symptoms or diseases of said listing;
i. analyzing compounds related in f. and h. for similarities and distinctions;
j. querying at least one structured database for negative assessments of compounds related in f. and h.;
k. correlating negative assessments with similarities and distinctions of i.;
l. associating chemical structure with said similarities and distinctions;
m. selecting chemical structural features minimizing said negative assessments;
n. designing a chimeric compound or a library of chimeric compounds maintaining at least one feature of at least one compound related in f. and h. while discarding one or more chemical feature selected in m.; and
o. producing at least one compound designed in n.

### Claim 8 (depends on 7)

The method of claim 7 further comprising:
e1. querying at least one structured database for a compound previously applied to modulate at least one characteristic associated with said first symptom or said first disease to obtain a compound identifying record; and
in f. selecting a chemical compound relating to said compound identifying record.

### Claim 9 (depends on 1)

A pharmaceutical composition identified in accordance with claim 1.

### Claim 10 (depends on 9)

The composition of claim 9 comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound.

### Claim 11 (depends on 2)

A pharmaceutical composition identified in accordance with claim 2.

### Claim 12 (depends on 11)

The composition of claim 11 comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound.

### Claim 13 (depends on 7)

A pharmaceutical composition comprising a compound produced in accordance with claim 7.

### Claim 14 (depends on 13)

The composition of claim 13 comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13 in a delivery format selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray.

### Claim 16 (depends on 9)

The composition of claim 9 comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C4 (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ9-tetrahydrocannabinolic acid A (THCA-A); Δ9-tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ9-tetrahydrocannabinol, THC); Δ9-tetrahydrocannabinolic acid-C4 (THCA-C4); Δ9-tetrahydrocannabinol-C4 (THC-C4); Δ9-tetrahydrocannabivarinic acid (THCVA); Δ9-tetrahydrocannabivarinic (THCV); Δ7-cis-isotetrahydrocannabivarin; Δ9-tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ8-tetrahydrocannabinolic acid (Δ8-TCA); Δ8-tetrahydrocannabinol (Δ8-THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ9-cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ9-tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA−), and dihydrolipoate (DLA−); vitamin E, vitamin C, riboflavin (B2); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate.

### Claim 17 (depends on 16)

The composition of claim 16 wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin.

### Claim 18 (depends on 11)

The composition of claim 11 comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C4 (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ9-tetrahydrocannabinolic acid A (THCA-A); Δ9-tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ9-tetrahydrocannabinol, THC); Δ9-tetrahydrocannabinolic acid-C4 (THCA-C4); Δ9-tetrahydrocannabinol-C4 (THC-C4); Δ9-tetrahydrocannabivarinic acid (THCVA); Δ9-tetrahydrocannabivarinic (THCV); Δ7-cis-isotetrahydrocannabivarin; Δ9-tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ8-tetrahydrocannabinolic acid (Δ8-TCA); Δ8-tetrahydrocannabinol (Δ8-THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ9-cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ9-tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA−), and dihydrolipoate (DLA−); vitamin E, vitamin C, riboflavin (B2); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate.

### Claim 19 (depends on 18)

The composition of claim 18 wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin.

### Claim 20 (depends on 13)

The composition of claim 13 comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C4 (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ9-tetrahydrocannabinolic acid A (THCA-A); Δ9-tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ9-tetrahydrocannabinol, THC); Δ9-tetrahydrocannabinolic acid-C4 (THCA-C4); Δ9-tetrahydrocannabinol-C4 (THC-C4); Δ9-tetrahydrocannabivarinic acid (THCVA); Δ9-tetrahydrocannabivarinic (THCV); Δ7-cis-isotetrahydrocannabivarin; Δ9-tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ8-tetrahydrocannabinolic acid (Δ8-TCA); Δ8-tetrahydrocannabinol (Δ8-THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ9-cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ9-tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA−), and dihydrolipoate (DLA−); vitamin E, vitamin C, riboflavin (B2); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate.

### Claim 21 (depends on 20)

The composition of claim 20 wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin.

### Claim 22 (depends on 1)

The method of claim 1 wherein said new pharmaceutical composition is applied to treating a second symptom or second disease wherein said symptom is not identical to said second symptom or said disease is not identical to said second disease.

### Claim 23 (depends on 2)

The method of claim 2 wherein said new pharmaceutical composition is applied to treating a second disease wherein said first disease is not identical to said second disease.

### Claim 24 (depends on 7)

The method of claim 7 wherein said new pharmaceutical composition is applied to treating a second symptom or second disease wherein said first symptom is not identical to said second symptom or said first disease is not identical to said second disease.
